Furthermore, TNS4 is downregulated in paclitaxel-resistant PC-3 and DU145 prostate cancer cells, where its expression negatively correlates with EGFR levels, indicating that TNS4 exerts anti-tumor effects via EGFR inhibition [90]. This evidence concerns the gene EGFR and prostate carcinoma.